These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 29874936)

  • 21. Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration.
    Hong YD; Villalonga-Olives E; Perfetto EM
    Value Health; 2019 Aug; 22(8):925-930. PubMed ID: 31426934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do investors value the FDA orphan drug designation?
    Miller KL
    Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of Expedited Programs in the United States on Oncology Drug Development in Japan.
    Tanaka M; Matsumaru N; Tsukamoto K
    Ther Innov Regul Sci; 2019 Mar; 53(2):199-206. PubMed ID: 29732928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breakthrough Therapy Designation: CDER Analysis of Requests 4 Years Into the Program.
    Conrad R; Taylor K; Raggio M; Harrington A; Stark G; Kish A; Bertha A
    Ther Innov Regul Sci; 2017 Jul; 51(4):509-515. PubMed ID: 30227048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis.
    Garbade SF; Zielonka M; Mechler K; Kölker S; Hoffmann GF; Staufner C; Mengel E; Ries M
    PLoS One; 2020; 15(4):e0230898. PubMed ID: 32267884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases.
    Sachs-Barrable K; Conway J; Gershkovich P; Ibrahim F; Wasan KM
    Drug Dev Ind Pharm; 2014 Nov; 40(11):1429-34. PubMed ID: 24512098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug development for exceptionally rare metabolic diseases: challenging but not impossible.
    Putzeist M; Mantel-Teeuwisse AK; Wied CC; Hoes AW; Leufkens HG; de Vrueh RL
    Orphanet J Rare Dis; 2013 Nov; 8():179. PubMed ID: 24237580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA's Expedited Programs and Their Impact on the Availability of New Therapies.
    Damle N; Shah S; Nagraj P; Tabrizi P; Rodriguez GE; Bhambri R
    Ther Innov Regul Sci; 2017 Jan; 51(1):24-28. PubMed ID: 30235999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL; Shields KM
    Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies.
    Miller KL; Kraft S; Ipe A; Fermaglich L
    Expert Opin Orphan Drugs; 2022 Mar; 9(11-12):265-272. PubMed ID: 35548705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.
    Michaeli DT; Michaeli T; Albers S; Michaeli JC
    J Natl Cancer Inst; 2024 Feb; 116(2):216-229. PubMed ID: 37824202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.
    Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2015 Jan; 97(1):29-36. PubMed ID: 25670381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O; Zhou Y
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.